Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06373458 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion pushed from Aug 2027 to Jan 2028v6
  2. Primary completion date: Mar 2026 to Aug 2027
    • Study completion date: May 2026 to Aug 2027
    v5
  3. Start date changed from estimate of Sep 1, 2024 to Aug 13, 2024v4
  4. Start date: Jun 30, 2024 to Sep 1, 2024v3
  5. Start date: Apr 15, 2024 to Jun 30, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3/TEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis.
Trial Details
NCT Number NCT06373458
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: Pfizer
Conditions
(from sponsor)		 Keloid
Related terms Keloid
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov